Equities Analysts Issue Forecasts for Lion Biotechnologies, Inc.’s Q3 2018 Earnings (NASDAQ:IOVA)

Lion Biotechnologies, Inc. (NASDAQ:IOVA) – Equities researchers at FBR & Co issued their Q3 2018 EPS estimates for shares of Lion Biotechnologies in a research report issued on Tuesday, Zacks Investment Research reports. FBR & Co analyst M. Kumar expects that the biotechnology company will post earnings of ($0.34) per share for the quarter. FBR & Co currently has a “Buy” rating and a $17.50 target price on the stock. FBR & Co also issued estimates for Lion Biotechnologies’ FY2019 earnings at ($1.35) EPS.

Lion Biotechnologies (NASDAQ:IOVA) last posted its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://ledgergazette.com/2017/11/13/fbr-co-weighs-in-on-lion-biotechnologies-inc-s-q3-2018-earnings-iova.html.

IOVA has been the subject of several other research reports. Oppenheimer Holdings, Inc. set a $13.00 target price on shares of Lion Biotechnologies and gave the stock a “buy” rating in a research note on Monday, September 11th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Lion Biotechnologies in a research note on Wednesday, August 16th. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of Lion Biotechnologies in a research note on Friday, September 1st. B. Riley boosted their price objective on shares of Lion Biotechnologies from $17.50 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, November 1st. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Lion Biotechnologies in a research note on Wednesday, August 16th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $14.53.

Lion Biotechnologies (NASDAQ:IOVA) opened at $8.05 on Thursday. Lion Biotechnologies has a 12 month low of $4.45 and a 12 month high of $8.60.

Hedge funds have recently added to or reduced their stakes in the business. Victory Capital Management Inc. purchased a new position in Lion Biotechnologies in the 2nd quarter worth approximately $19,013,000. FMR LLC purchased a new position in Lion Biotechnologies in the 2nd quarter worth approximately $20,833,000. Frazier Management LLC purchased a new position in Lion Biotechnologies in the 2nd quarter worth approximately $15,209,000. Rhumbline Advisers purchased a new position in Lion Biotechnologies in the 2nd quarter worth approximately $468,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in Lion Biotechnologies in the 2nd quarter worth approximately $1,538,000. 66.64% of the stock is owned by institutional investors and hedge funds.

Lion Biotechnologies Company Profile

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Get a free copy of the Zacks research report on Lion Biotechnologies (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lion Biotechnologies (NASDAQ:IOVA)

Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply